Forward to the Past: The Case for Quantitative PET Imaging.

Area of Science:

• Medical Imaging
• Nuclear Medicine
• Radiochemistry

Background:

• Positron Emission Tomography (PET) evolved from measuring pathophysiologic processes to detecting increased uptake for brain activation and oncology staging.
• The focus on sensitivity, particularly with 18F-FDG, has historically overshadowed PET's quantitative capabilities.
• Recent trends emphasize PET's role in drug development and precision medicine for monitoring therapy response.

Purpose of the Study:

• To review the importance of quantitative Positron Emission Tomography (PET) in modern medicine.
• To highlight the risks associated with using simplified, semiquantitative PET methods without validation.
• To advocate for a balance between accuracy and simplicity in PET quantification for clinical applications.

Main Methods:

• Review of existing literature and case examples illustrating the impact of quantitative PET.
• Analysis of the evolution of PET imaging techniques and their applications.
• Discussion on the challenges and necessity of validated quantitative methods in PET.

Main Results:

• Simplified semiquantitative PET methods can yield inaccurate or misleading results, compromising diagnostic and therapeutic assessments.
• Overemphasis on sensitivity in PET has led to underutilization of its quantitative potential.
• Lack of proper validation for simplified PET methods can lead to wasted resources and ethical concerns, particularly in drug development.

Conclusions:

• Accurate quantification is essential for leveraging PET's full potential in precision medicine and drug development.
• Careful validation studies are required to establish the optimal balance between accuracy and simplicity in PET methods.
• The adoption of unvalidated simplified PET approaches poses risks to research integrity and patient care.